Engineering Commons^™

How To Make Cement And Concretes With Lower Co2 Emissions, Ellis Gartner

CO2 Summit: Technology and Opportunity

No abstract provided.

Minimization Of Embodied Energy In Reinforced Concrete, Emil Simiu

CO2 Summit: Technology and Opportunity

No abstract provided.

Greenhouse Gas Capture And Mitigation Techniques For Different Industries, Trapti Chaubey

CO2 Summit: Technology and Opportunity

No abstract provided.

Metabolic Engineering Of A Strain Of Saccharomyces Cerevisiae Capable Of Utilizing Xylose For Growth And Ethanol Production, Ashley Fulton

CO2 Summit: Technology and Opportunity

No abstract provided.

Monitoring Consumption - A First Step In Developing An Online Energy Management Solution, Paul Feder

CO2 Summit: Technology and Opportunity

No abstract provided.

Greenhouse Gas Capture And Mitigation Techniques For Different Industries, Trapti Chaubey

CO2 Summit: Technology and Opportunity

No abstract provided.

Enhanced Photosynthetic Growth, Biodiesel And Electricity Production Using C. Vulgaris And P. Putida/S. Cerevisiae, Pranabendu Mitra

CO2 Summit: Technology and Opportunity

No abstract provided.

Analysis Of Global Warming Mitigation By White Reflecting Surfaces, Federico Rossi

CO2 Summit: Technology and Opportunity

No abstract provided.

Biofuels And Bio-Based Chemicals: Opportunities & Barriers, Joseph B. Powell

CO2 Summit: Technology and Opportunity

No abstract provided.

Challenges And Opportunities In Developing A Sustainable Biomass Infrastructure, Prabhakar Nair

CO2 Summit: Technology and Opportunity

No abstract provided.

Co2 Conversion To Organic Compounds And Polymeric Precursors, Jussara Lopes De Miranda

CO2 Summit: Technology and Opportunity

No abstract provided.

The Role Of Technology In Energy Outlook, Nazeer Bhore

CO2 Summit: Technology and Opportunity

No abstract provided.

Energy Production In A Carbon-Constrained World, George Richards

CO2 Summit: Technology and Opportunity

No abstract provided.

Ghg Impact Of Using Fast Pyrolysis Oil For Electricity And Biofuel Generation, Tom N. Kalnes

CO2 Summit: Technology and Opportunity

No abstract provided.

Escherichia Coli Plasmid Dna Fermentation: Strain And Process-Specific Effects On Vector Yield, Quality, And Transgene Expression, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, James Williams

Vaccine Technology III

To commercialize DNA medicines, industrial plasmid DNA manufacturing processes are needed which meet the quality, economy, and scale requirements projected for future products. NTC has developed an inducible fed-batch fermentation process that incorporates novel cell bank and fermentation process innovations that reduce plasmid mediated metabolic burden. This process also incorporates a scalable plasmid induction profile that, in combination with vector backbone modifications that double fermentation productivity compared to existing high copy vectors such as pVAX1 and gWIZ, form a generic plasmid DNA production platform driving high plasmid yields up to 2.6 g/L, with specific yields of 5% of total dry …

After The License Approval: How Analytics Can Keep You In The Market, Robert Sitrin

Vaccine Technology III

Getting a BLA approved for a new vaccine can be a daunting task, but keeping the market supplied after licensure of a successful vaccine can be an even bigger challenge. Analytics can play an important role in keeping product supplied to the marketplace, especially during the critical launch phase The talk will describe the application of analytical comparability to GARDASIL®, Merck’s novel new vaccine to prevent cervical cancer, in order to bridge product produced by a launch facility to that produced by a scale-up facility without the need for a clinical trial. This effort assured a smooth transition of supply …

Nipah/Hendra: Understanding The Links Between Human And Veterinary Emerging Diseases, Jules Minke

Vaccine Technology III

Animals constitute an important source of infectious diseases for humans and the majority of recent emerging diseases in humans are zoonotic. Infections occur through direct or indirect transmission from wildlife reservoirs or via the food chain. Nipah and Hendra viruses have recently joined the growing list of viruses that emerged from bats to cause serious disease in humans and livestock. Although the precise mode of virus transmission is not fully understood, human infection appears to be the result of close contact with infected horses and pigs that act as amplifying hosts. Improved control strategies are necessary to reduce the transmission …

Development Of Protein Capsular Matrix Vaccine (Pcmv) Technology, Kevin P. Killeen, Ann Thanawastien, Tom Griffin

Vaccine Technology III

Matrivax R&D Corp. is a start-up biotechnology company with R&D operations located in Boston, USA and a vaccine pilot facility in Haikou, China. We are developing a proprietary vaccine process that entraps polysaccharides in a cross-linked protein ‘carrier’ or matrix, termed Protein Capsular Matrix Vaccine (PCMV), as an alternative to conjugate vaccine technology. Despite highly efficacious pneumococcal vaccines such as Prevnar®, S. pneumoniae causes > 1 million deaths worldwide annually. Likewise, typhoid fever afflicts ~16 million people, resulting in 600,000 deaths despite effective vaccines such as Typhim Vi® and Ty21a. The premise is that inexpensive,efficacious polysaccharide vaccines that elicit TH-cell ‘memory’ …

A Vaccine Prototype Using Baculovirus Expression System For The Control Of Avian Influenza Virus, Mauricio Realpe, R. Mora, L. Castellanos, F. Robles, C. González-Hernández

Vaccine Technology III

A clade 1 sequence of H5 haemaglutinin from an Asian Avian H5N1 isolate was used as a the template to chemically synthetize a codon optimized version for expression in insect cells. A single clone was chosen for expression optimization and changes were introduced in order to maximize the amount of protein to be produced and to resemble another sequence demonstrated to be present in an isolate causing disease in Humans.

Preliminary analysis at lab scale have shown promising yields of the haemaglutinin using an activity titration assay and an ELISA-based detection method. Optimization of the cell seeding, MOI, and time …

Rabies Virus Glycoprotein (Rvgp) Expression In Drosophila S2 Cells And By Semliki Forest Virus (Sfv). Synthesis And Protection Studies, Carlos Pereira

Vaccine Technology III

Here we report the utilization of Drosophila melanogaster Schneider 2 (S2) cells and the Semliki Forest Virus (SFV) expression system to produce the rabies virus glycoprotein (RVGP). Although they represent different expression systems, they offer similar advantages in generating high-level expression of functional membrane proteins. They are both relatively easy and safe to handle and are scalable. RVGP synthesized by S2 cells and SFV carrying an mRNA coding for RVGP (SFV-RVGP) were assayed in mouse protection studies. We have constructed S2 gene vectors with the hygromycin selection gene (H) in which the RVGP gene is inserted under the control of …

Human Cells For Prostate Cancer Vaccine Therapy - The Impact Of Centrifugation Upon Key Product Quality Attributes, Michael Delahaye, Katherine Lawrence, Carol Chu Mike Hoare, Stephen Ward

Vaccine Technology III

Centrifugation is a unit operation used within a wide range of bioprocesses, including the production of a whole cell cancer vaccine to treat Hormone Refractory Prostate Cancer (HRPC) which has been tested in Phase II clinical trials. To quantify the effect of centrifugation-related stresses upon a whole cell vaccine population, a design of experiments (DOE) based investigation at micro-scale was implemented. Qualification of the cells may be by membrane integrity and by surface marker density as well as cytokines released and retained during bioprocessing. These and possibly other factors combine to affect the biopotency of the cells and their clinical …

Challenges In Confronting Pandemic Influenza Using Novel Adjuvanted Vaccines, Louis F. Fries

Vaccine Technology III

Pandemic influenza is a recurring threat throughout history. Characterized by rapid spread and high attack rate, the features of pandemic influenza are grounded in the lack of immunologic experience with pandemic virus subtypes in the majority of the human population alive during the outbreak. Immunization is regarded as a key tool in preparing for, and mitigating, pandemic influenza. Unfortunately, capacity to manufacture sufficient inactivated influenza antigen by currently-licensed processes remains challenging, and this problem is amplified by the very short timeline for production and distribution that may be available. GSK has addressed the pandemic influenza challenge by application of the …

Development Of A Multi-Dose Formulation For Prevnar 13™, Lakshmi Khandke, Cindy Yang, Jingrun Fan, Hanyoung Han, Ksenia Krylova Abbas Rashidbaigi, Bruce A. Green, Kathrin U. Jansen

Vaccine Technology III

Streptococcus pneumoniae causes up to a million cases per year of invasive disease in young children and infants, most occurring in developing countries. Pfizer is partnering with WHO and the GAVI alliance to support the developing world on immunization against pneumococcal disease. Prevnar 13™ is currently approved for the prevention of invasive pneumococcal disease in twenty seven countries. If used widely, this pneumococcal conjugate vaccine could prevent hundreds of thousands of additional cases of child mortality each year.

Use of single-dose preservative-free vaccine formulations will raise the overall cost of vaccination programs and may jeopardize the effectiveness of immunization programs …

Purification Process Development Of Protein Subunit Based Vaccine Candidates Produced Using Recombinant E. Coli Expression System (Part - I), Davinder Chawla, Yan-Ping Yang

Vaccine Technology III

Proteins are key components of prophylactic vaccines against infectious diseases. Protein subunit based vaccine is an attractive alternative to the traditional detoxified bacterial or inactivated viral vaccine approach due to its highly purified and well characterized product nature. Purification of protein antigens to achieve consistent product purity and quality is an integral part of the protein subunit vaccine product development process. Expression levels of the recombinant proteins in bacterial expression system may be extremely high following rapid technology advancement. The challenges and approaches used to develop purification processes for novel protein vaccine candidates expressed at g/L level will be discussed.

Innovative Therapeutic Cancer Vaccines In Cuba: An Update, Luis Enrique Fernández

Vaccine Technology III

Worldwide cancer affects more than 10 million new people each year while other 22 million are living with this devastating disease.

Cancer vaccines are the newest weapon in the battle against this disease, specifically increasing body's natural abilities to halt tumour progression. Currently, 141 distinct projects are at different stages of clinical development.

The Cuban Biotech System of Institutions has been actively involved in this field for almost 20 years, resulting that 8 innovative therapeutic cancer vaccine projects are currently under clinical investigation.

The main focus of these projects is to impact the principal cancer localizations afecting Cuban population, like …

Vaccine Stabilization – Research, Commercialization, And Impact, Ray Cummings, Debra Kristensen, Dexiang Chen, Michel Zaffran

Vaccine Technology III

Improving the stability of vaccines and removing vaccines from refrigerated storage for all or part of their shelf life have been proposed as strategies to help ensure vaccine effectiveness and to mitigate cold chain storage capacity constraints and escalating costs associated with the introduction of new vaccines into developing countries. Over the last six years, PATH has conducted research on stabilization of measles, Haemophilus influenzae type b (Hib), hepatitis B, enterotoxgenic Escherichia coli, conjugate meningococcal A, and pentavalent (Diphtheria-Tetanus-Pertussis-hepatitis B-Hib) vaccines in collaboration with 22 technical partners and 10 vaccine development groups. Results will be shared and include marked improvement …

Purification Process Development Of Protein Subunit Based Vaccine Candidates Produced Using Recombinant E. Coli Expression System (Part - Ii), Davinder Chawla, Yan-Ping Yang

Vaccine Technology III

Proteins are key components of prophylactic vaccines against infectious diseases. Protein subunit based vaccine is an attractive alternative to the traditional detoxified bacterial or inactivated viral vaccine approach due to its highly purified and well characterized product nature. Purification of protein antigens to achieve consistent product purity and quality is an integral part of the protein subunit vaccine product development process. Expression levels of the recombinant proteins in bacterial expression system may be extremely high following rapid technology advancement. The challenges and approaches used to develop purification processes for novel protein vaccine candidates expressed at g/L level will be discussed.

Influence Of Host Cell Defence During Influenza Vaccine Production In Mdck Cells, Timo Frensing, Claudius Seitz, Bjoern Heynischotto-Von-Guericke, Udo Reichl

Vaccine Technology III

For cell culture-based influenza vaccine production virus yield optimisation is of crucial importance. In particular, with the recent threat of the new H1N1 pandemic, not only seasonal vaccines but also pre-/pandemic vaccines have to be supplied in large quantities. In vivo influenza replication is limited by the immune system, but for production cell lines the impact of cellular defence mechanisms on virus yield is unknown. In influenza-infected adherent Madin-Darby canine kidney (MDCK) cells the interferon (IFN) response and subsequent induction of the antiviral state was monitored. Virus yield and host cell signalling intensity were strain-dependent. By over-expression of viral antagonists …

Process Scale-Up And Optimization For Production Of High Efficacy Oral Rabies Vaccine, Amine Kamen, Chun Fang Shen, Stephane Lanthier, Danielle Jacob, Johnny Montes, Andrew Beresford

Vaccine Technology III

Rabies is an important causative agent of disease resulting in an acute infection of the nervous system and death of the individual. Rabies remains an important public health program in developing countries, and the indigenous threat of rabies continues in developed countries because of wildlife reservoirs. Globally, there are about 55,000 fatal human cases of rabies each year [WHO, 2007]. Control of rabies in wildlife remains an important challenge for government offices.

There are numbers of rabies vaccines commercially available for controls of wildlife rabies. However, these vaccines currently distributed to wildlife do not effectively immunize all at-risk species, especially …

Final Conference Program, Barry Buckland, John Aunins, Paula Marques Alves, Kathrin Jansen

Vaccine Technology III

List of talks during the conference.